A 2026 expert consensus guideline outlines how therapeutic carbohydrate reduction may help improve blood sugar control, insulin resistance, and other markers of metabolic health.
For people living with type 2 diabetes or insulin resistance, nutrition can play an important role in managing metabolic health. But what does the research say about reducing carbohydrates as a therapeutic approach?
A new guideline published in the Journal of Metabolic Health explores this question, bringing together expert recommendations for implementing therapeutic carbohydrate reduction (TCR) in clinical practice.
The guideline provides a framework for healthcare professionals to help patients use carbohydrate reduction safely, effectively, and in ways that fit their individual needs.
What Is Therapeutic Carbohydrate Reduction?
Therapeutic carbohydrate reduction is a nutritional approach that intentionally reduces carbohydrate intake to help manage metabolic conditions such as type 2 diabetes, obesity, and insulin resistance.
Unlike a one-size-fits-all diet, TCR can be adjusted according to an individual's health goals, medical history, and nutritional needs.
The guideline describes several levels of carbohydrate reduction, ranging from moderate restriction to very-low-carbohydrate ketogenic approaches.
Importantly, nutritional ketosis is not required for everyone to experience metabolic benefits.
The emphasis is on choosing nutrient-dense whole foods, consuming adequate protein, and tailoring carbohydrate intake to individual circumstances.
What Did the Experts Agree On?
The guideline was developed using a structured Delphi consensus process, in which experts reviewed and refined recommendations through multiple rounds of feedback.
In the final round, 26 participants completed the survey, and all 18 consensus statements met the predefined agreement threshold.
The resulting recommendations address several important areas of metabolic health.
1. Carbohydrate Reduction May Improve Blood Sugar Control
Reducing dietary carbohydrates can help lower blood glucose levels and improve glycemic control in people with type 2 diabetes.
The guideline also discusses research showing that some individuals may experience reduced medication requirements or achieve type 2 diabetes remission with appropriate dietary changes and clinical support.
However, results vary, and remission does not mean diabetes is permanently cured.
2. Insulin Resistance Is an Important Treatment Target
Insulin resistance occurs when the body's cells become less responsive to insulin, making it more difficult to regulate blood sugar effectively.
It is closely associated with type 2 diabetes and other metabolic conditions.
The guideline identifies carbohydrate reduction as one approach that may help address several metabolic abnormalities associated with insulin resistance.
3. Whole Foods and Adequate Nutrition Matter
Therapeutic carbohydrate reduction is not simply about removing carbohydrates.
The guideline emphasizes a nutritionally adequate approach built around whole foods, including:
-
Protein sources such as meat, fish, poultry, and eggs
-
Non-starchy vegetables
-
Healthy fats from whole-food sources
-
Lower-sugar fruits, depending on individual carbohydrate targets
Protein intake should be individualized to support muscle maintenance, physical function, and overall nutritional needs.
The approach can also be adapted to accommodate cultural food preferences and individual lifestyles.
4. Dietary Changes Should Be Individualized
Not everyone needs the same level of carbohydrate reduction.
Some individuals may benefit from moderate changes, while others may require a more structured low-carbohydrate approach to achieve specific therapeutic goals.
The guideline emphasizes that dietary recommendations should account for medical conditions, medication use, nutritional requirements, personal preferences, and long-term sustainability.
5. Medical Monitoring Is Essential
One of the most important considerations when reducing carbohydrates is medication safety.
People taking insulin or medications that increase insulin secretion may experience low blood sugar if carbohydrate intake changes without appropriate medication adjustments.
Certain medications, including SGLT2 inhibitors, also require special consideration because of the risk of ketoacidosis.
For these reasons, therapeutic carbohydrate reduction should be implemented with appropriate healthcare supervision, particularly for individuals managing diabetes with medication.
Never stop or reduce prescribed diabetes medication without guidance from your healthcare professional.
Can Carbohydrate Reduction Support Long-Term Metabolic Health?
The guideline concludes that therapeutic carbohydrate reduction can be a practical nutritional intervention for several metabolic disorders.
It also recognizes that successful long-term implementation depends on individual preferences, adequate nutrition, ongoing support, and appropriate clinical monitoring.
The authors acknowledge that further research is needed to better understand outcomes across different populations and clinical settings.
This is an expert consensus guideline informed by existing research, rather than a new clinical trial or a systematic review with formally graded evidence.
What This Means for People Living With Diabetes
The findings reinforce the importance of individualized nutrition in diabetes management.
For people with type 2 diabetes or insulin resistance, carbohydrate reduction may be one useful option for improving blood sugar control and other metabolic health markers.
The appropriate approach will depend on each person's health needs, treatment plan, and ability to maintain dietary changes over time.
At the American Diabetes Society, we believe individuals should have access to evidence-informed education that helps them make informed decisions alongside their healthcare professionals.
Understanding the available nutritional approaches is an important part of that process.
Read the Original Research
Original article: A Delphi consensus-based guideline for the implementation of therapeutic carbohydrate reduction in metabolic disorders
Authors: Sarah M. Rice, Laura A. Buchanan, Matthew W. Calkins, Mark T. Cucuzzella, Robert Cywes, Pamela L. Devine, Miriam Kalamian, Tro Kalayjian, Douglas B. Reynolds, and Eric C. Westman.
Journal: Journal of Metabolic Health, Volume 9, Issue 1 (2026), Article a152.
Published: October 2, 2026
Original publication: https://doi.org/10.4102/jmh.v9i1.152
Attribution and License
This article is adapted from the original publication by Rice et al. (2026), published in the Journal of Metabolic Health, and licensed under the Creative Commons Attribution 4.0 International License.
Changes made: The original research guideline has been summarized, reorganized, and rewritten in accessible language for a general audience. Technical discussions and detailed clinical recommendations have been condensed. Additional explanatory language and a reader-focused medical safety disclaimer have been included.
This adaptation is not endorsed by the original authors or publisher.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Dietary changes can affect blood glucose levels and medication requirements. Individuals with diabetes, especially those taking insulin, sulfonylureas, or SGLT2 inhibitors, should consult their healthcare professional before making significant dietary changes.




Leave a comment
This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.